| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | CCLE | pan-cancer | AAC | -0.29 | 6e-09 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.21 | 5e-08 |
| mRNA | FK866 | CTRPv2 | pan-cancer | AAC | 0.22 | 1e-07 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.26 | 2e-07 |
| mRNA | FK866 | GDSC1000 | pan-cancer | AAC | 0.18 | 2e-07 |
| mRNA | AZD6244 | CTRPv2 | pan-cancer | AAC | -0.2 | 4e-07 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | -0.2 | 4e-07 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | -0.2 | 9e-07 |
| mRNA | selumetinib:MK-2206 (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.19 | 1e-06 |
| mRNA | BIBW2992 | CTRPv2 | pan-cancer | AAC | -0.2 | 1e-06 |